뉴로원 메디컬 테크놀로지스NMTC 주가

♻️ 재탕[SD] SD — SPECIALIZED DISCLOSURE REPORT

[SD] SD — SPECIALIZED DISCLOSURE REPORT

NeuroOne Medical Technologies To Restate Q1 2026 Financial Statements; Restatement Corrects $0.5M Revenue Overstatement For Q1 2026; Net Loss Understated By $0.3M For Q1 2026; Restatement Does Not Affect Fy2026 Product Revenue Guidance Or Cash Position

-SEC Filing

♻️ 재탕[8-K] 중대 사건 — CURRENT REPORT

12 Health Care Stocks Moving In Tuesday's After-Market Session

NeuroOne Medical Technologies Corp (NMTC) Q2 2026 Earnings Call Highlights: Strong Product ...

NeuroOne Medical Technologies Corp (NMTC) reports significant revenue growth and strategic advancements, despite facing profitability and cash flow challenges.

NeuroOne Medical Technologies (NASDAQ:NMTC) Fiscal Q2 Revenue Surges 72% But Misses Estimates, Shares Dip

NeuroOne Medical (NMTC) reported 72% product revenue growth to $2.4M in Q2 2026, driven by OneRF ablation adoption, but fell short of analyst estimates, with shares dipping 2.5% pre-market.

NeuroOne Reports Fiscal Q2 2026 Financial Results and Provides Corporate Business Update

Product Revenue of $2.4 Million up 72% Year Over Year Successfully Completed 16 Trigeminal Neuralgia Cases to Date, With All Patients Reportedly Pain Free* Management to Host Conference Call Today at 8:30 a.m. Eastern Time EDEN PRAIRIE, MINN. - M...

♻️ 재탕NeuroOne Medical Tech Q2 2026 Earnings Call Transcript

♻️ 재탕Transcript : NeuroOne Medical Technologies Corporation, Q2 2026 Earnings Call, May 12, 2026

Presentation Operator MessageOperator Good day, ladies and gentlemen, and welcome to NeuroOne Medical Technologies Corporation's Second Quarter Fiscal 2026 Financial Results Conference Call.